TherapeuticsMD, Inc. (TXMD): auditor change — TherapeuticsMD appoints CRI as new auditor; prior reports included going concern emphasis

TherapeuticsMD, Inc.

Audit Committee approved CRI as independent auditor effective Jan 15, 2026; BPB dismissed.
Change due to CRI acquiring certain assets of BPB's capital markets practice.
No disagreements or reportable events with BPB during fiscal 2025 and 2024.
BPB's reports for FY 2024 and 2023 included an explanatory paragraph on going concern uncertainty.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

TherapeuticsMD, Inc. engaged Carr, Riggs & Ingram, L.L.C. as its auditor.

Action: engagement
Auditor: Carr, Riggs & Ingram, L.L.C.

Exact text from the filing

On January 15, 2026, the Audit Committee of the Board of Directors of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), approved the appointment of Carr, Riggs & Ingram, L.L.C. (“CRI”) as the Company’s independent registered public accounting firm, effective immediately.

View on SEC.gov

6 auditor changes filed in the last 30 days. Browse all auditor changes →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-005779

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.